Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
OtherPROCEDURE GUIDELINES

Procedure Guideline for Tumor Imaging with 18F-FDG PET/CT 1.0

Dominique Delbeke, R. Edward Coleman, Milton J. Guiberteau, Manuel L. Brown, Henry D. Royal, Barry A. Siegel, David W. Townsend, Lincoln L. Berland, J. Anthony Parker, Karl Hubner, Michael G. Stabin, George Zubal, Marc Kachelriess, Valerie Cronin and Scott Holbrook
Journal of Nuclear Medicine May 2006, 47 (5) 885-895;
Dominique Delbeke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Edward Coleman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Milton J. Guiberteau
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manuel L. Brown
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henry D. Royal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barry A. Siegel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David W. Townsend
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lincoln L. Berland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Anthony Parker
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karl Hubner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael G. Stabin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George Zubal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Kachelriess
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Valerie Cronin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott Holbrook
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Tables

    • View popup
    TABLE 1

    18F-FDG Radiation Dosimetry for Adults and Children

    PatientIntravenously administered activity, MBq/kg (mCi/kg)Organ receiving the largest radiation dose, mGy/MBq (rads/mCi)Effective dose, mSv/MBq (rems/mCi)
    Adult370–740 (10–20)Bladder, 0.16* (0.59)0.019 (0.070)
    Child (5 y old)5.18–7.4 (0.14–0.20)Bladder, 0.32† (1.2)0.050 (0.18)
    • ↵* Voiding interval, 3.5 h. Changes in bladder wall dose are approximately linear with changes in voiding interval; therefore, for a voiding interval of 2.0 h, dose to bladder wall would change by a factor of 2/3.5.

    • ↵† Voiding interval, 2.0 h.

    • Data are from International Commission on Radiological Protection. Radiation Dose to Patients from Radiopharmaceuticals. St. Louis, MO: Elsevier; 2000:49. ICRP publication 80.

    • View popup
    TABLE 2

    Summary of PET/CT On-The-Job Training Requirements

    TrainingBoard certificationNo. of PET/CT interpretations (supervised)*No. of CT interpretations (supervised)†PET/CT CME creditsCT CME credits
    Nuclear medicineABNM1505008100
    Diagnostic radiology (recent CT)‡ABR15035
    Nuclear radiology (recent CT)‡ABR1508
    Radiology (recent CT)‡ABR and ABNM1508
    Diagnostic radiology (no recent CT)ABR15050035100
    • ↵* Supervision should be performed by qualified nuclear medicine physicians or diagnostic radiologists who have interpreted more than 500 PET/CT studies.

    • ↵† Supervision should be performed by qualified diagnostic radiologists as defined in American College of Radiology Practice Guidelines for Performing and Interpreting Diagnostic Computed Tomography. CT cases should include reasonable distribution of head and neck, chest, abdomen, and pelvis.

    • ↵‡ Includes radiologists or nuclear radiologists with recent experience in body CT (100 body CT cases/y for preceding 5 y).

    • ABNM = American Board of Nuclear Medicine.

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 47 (5)
Journal of Nuclear Medicine
Vol. 47, Issue 5
May 2006
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Procedure Guideline for Tumor Imaging with 18F-FDG PET/CT 1.0
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Procedure Guideline for Tumor Imaging with 18F-FDG PET/CT 1.0
Dominique Delbeke, R. Edward Coleman, Milton J. Guiberteau, Manuel L. Brown, Henry D. Royal, Barry A. Siegel, David W. Townsend, Lincoln L. Berland, J. Anthony Parker, Karl Hubner, Michael G. Stabin, George Zubal, Marc Kachelriess, Valerie Cronin, Scott Holbrook
Journal of Nuclear Medicine May 2006, 47 (5) 885-895;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Procedure Guideline for Tumor Imaging with 18F-FDG PET/CT 1.0
Dominique Delbeke, R. Edward Coleman, Milton J. Guiberteau, Manuel L. Brown, Henry D. Royal, Barry A. Siegel, David W. Townsend, Lincoln L. Berland, J. Anthony Parker, Karl Hubner, Michael G. Stabin, George Zubal, Marc Kachelriess, Valerie Cronin, Scott Holbrook
Journal of Nuclear Medicine May 2006, 47 (5) 885-895;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • I. PURPOSE
    • II. BACKGROUND INFORMATION AND DEFINITIONS
    • III. EXAMPLES OF CLINICAL OR RESEARCH APPLICATIONS
    • IV. PROCEDURE
    • V. QUALIFICATION OF PERSONNEL
    • VI. ISSUES REQUIRING FURTHER CLARIFICATION
    • VII. CONCISE BIBLIOGRAPHY
    • VIII. DISCLAIMER
    • IX. APPROVAL
    • Footnotes
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • Erratum
  • PubMed
  • Google Scholar

Cited By...

  • Dopamine D1 Receptor Agonist PET Tracer Development: Assessment in Nonhuman Primates
  • Effects of Repeated 131I-Meta-Iodobenzylguanidine Radiotherapy on Tumor Size and Tumor Metabolic Activity in Patients with Metastatic Neuroendocrine Tumors
  • Establishment of National DRL for CT in Hybrid Imaging Studies (The Second Phase of the National NM CT (PET) Dose Audit for Kuwait Population -2019)
  • SNMMI Procedure Standard/EANM Practice Guideline on Pediatric 18F-FDG PET/CT for Oncology 1.0
  • Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib
  • Assessing the Effect of Various Blood Glucose Levels on 18F-FDG Activity in the Brain, Liver, and Blood Pool
  • Progressive cranial neuropathy and uterine involvement in myeloid sarcoma
  • Is True Whole-Body 18F-FDG PET/CT Required in Pediatric Lymphoma? An IAEA Multicenter Prospective Study
  • Prognostic Value of Deep Learning PET/CT-Based Radiomics: Potential Role for Future Individual Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma
  • Use of a Qualification Phantom for PET Brain Imaging in a Multicenter Consortium: A Collaboration Between the Pediatric Brain Tumor Consortium and the SNMMI Clinical Trials Network
  • An International Survey of PET/CT Clinical Reporting
  • Biodistribution, Tumor Detection, and Radiation Dosimetry of 18F-5-Fluoro-2'-Deoxycytidine with Tetrahydrouridine in Solid Tumors
  • An International Survey on Clinical Reporting of PET/CT Examinations: A Starting Point for Cross-Specialty Engagement
  • Validation of Metabolically Active Tumor Volume and Total Lesion Glycolysis as 18F-FDG PET/CT-derived Prognostic Biomarkers in Chemorefractory Metastatic Colorectal Cancer
  • A Postreconstruction Harmonization Method for Multicenter Radiomic Studies in PET
  • Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma
  • Novel Method to Detect and Characterize 18F-FDG Infiltration at the Injection Site: A Single-Institution Experience
  • 18F-Tetrafluoroborate, a PET Probe for Imaging Sodium/Iodide Symporter Expression: Whole-Body Biodistribution, Safety, and Radiation Dosimetry in Thyroid Cancer Patients
  • Incidence of Brain Metastases on Follow-up 18F-FDG PET/CT Scans of Non-Small Cell Lung Cancer Patients: Should We Include the Brain?
  • Joint SNMMI-ASNC Expert Consensus Document on the Role of 18F-FDG PET/CT in Cardiac Sarcoid Detection and Therapy Monitoring
  • Quantitative Accuracy and Lesion Detectability of Low-Dose 18F-FDG PET for Lung Cancer Screening
  • Does PET SUV Harmonization Affect PERCIST Response Classification?
  • PET Imaging of Tissue Factor in Pancreatic Cancer Using 64Cu-Labeled Active Site-Inhibited Factor VII
  • Positron Emission Mammography Image Interpretation for Reduced Image Count Levels
  • Dose-Finding Quantitative 18F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic Malignancies
  • Molecular Imaging to Plan Radiotherapy and Evaluate Its Efficacy
  • Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma
  • Reduction of Patient Anxiety in PET/CT Imaging by Improving Communication Between Patient and Technologist
  • The importance of harmonizing interim positron emission tomography in non-Hodgkin lymphoma: focus on the Deauville criteria
  • 64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer
  • Prospective Study of Tailoring Whole-Body Dual-Modality [18F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography With Plasma Epstein-Barr Virus DNA for Detecting Distant Metastasis in Endemic Nasopharyngeal Carcinoma at Initial Staging
  • SNMMI/ASNC/SCCT Guideline for Cardiac SPECT/CT and PET/CT 1.0
  • Elevated 18F-FDG Levels in Blood and Organs After Angiotensin II Receptor Blocker Administration: Experiment in Mice Administered Telmisartan
  • Beta-2 Microglobulin as a Diagnostic Parameter in Non-Hodgkin Lymphoma: A Comparative Study with FDG-PET
  • Reporting Guidance for Oncologic 18F-FDG PET/CT Imaging
  • EANM/SNMMI Guideline for 18F-FDG Use in Inflammation and Infection
  • Clinical Utility of 18F-FDG Positron Emission Tomography and Computed Tomography in Patients With Suspected Cardiovascular Implantable Electronic Device Infection
  • Imaging of Multiple Myeloma and Related Plasma Cell Dyscrasias
  • Need for Standardization of 18F-FDG PET/CT for Treatment Response Assessments
  • Effect of Patient Arm Motion in Whole-Body PET/CT
  • Shortened Dynamic 18F-FDG PET
  • Patient Weight-Based Acquisition Protocols to Optimize18F-FDG PET/CT Image Quality
  • Could Different Hydration Protocols Affect the Quality of 18F-FDG PET/CT Images?
  • Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non-Small Cell Lung Cancer Treated with Erlotinib
  • Preliminary Study of 11C-Choline PET/CT for T Staging of Locally Advanced Nasopharyngeal Carcinoma: Comparison with 18F-FDG PET/CT
  • Standardization of Quantitative Imaging: The Time Is Right, and 18F-FDG PET/CT Is a Good Place to Start
  • Variations in Clinical PET/CT Operations: Results of an International Survey of Active PET/CT Users
  • Whole-Body 18F-FDG PET/CT: The Need for a Standardized Field of View--A Referring-Physician Aid
  • Do Hyperglycemia and Diabetes Affect the Incidence of False-Negative 18F-FDG PET/CT Studies in Patients Evaluated for Infection or Inflammation and Cancer? A Comparative Analysis
  • Reply: The Twilight Saga of Insulin Administration in Hyperglycemic Patients Undergoing 18F-FDG PET
  • The Twilight Saga of Insulin Administration in Hyperglycemic Patients Undergoing 18F-FDG PET
  • Odontogenic myxofibroma synchronous with primary angiosarcoma of the spleen
  • Expert Opinions on Positron Emission Tomography and Computed Tomography Imaging in Lymphoma
  • Comparison of Imaging Protocols for 18F-FDG PET/CT in Overweight Patients: Optimizing Scan Duration Versus Administered Dose
  • Standards for PET Image Acquisition and Quantitative Data Analysis
  • Prospective Evaluation of Physiologic Uptake Detected with True Whole-Body 18F-FDG PET/CT in Healthy Subjects
  • Impact of Intravenous Insulin on 18F-FDG PET in Diabetic Cancer Patients
  • The Effect of Renal Failure on 18F-FDG Uptake: A Theoretic Assessment
  • Contrast-Enhanced 18F-FDG PET/CT: 1-Stop-Shop Imaging for Assessing the Resectability of Pancreatic Cancer
  • The role of clinical imaging in oncological drug development
  • Significant Benefit of Multimodal Imaging: PET/CT Compared with PET Alone in Staging and Follow-up of Patients with Ewing Tumors
  • Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
  • Google Scholar

More in this TOC Section

  • Procedure Guideline for SPECT/CT Imaging 1.0
  • Procedure Guideline for Brain Death Scintigraphy
Show more Procedure Guidelines

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire